Novartis AGNVSNYSE
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank56
3Y CAGR-48.1%
5Y CAGR-23.5%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-48.1%/yr
Quarterly compound
5Y CAGR
-23.5%/yr
Recent deceleration
Percentile
P56
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 3.86% |
| Q3 2025 | -3.89% |
| Q2 2025 | 12.56% |
| Q1 2025 | -12.65% |
| Q4 2024 | 11.71% |
| Q3 2024 | 1.39% |
| Q2 2024 | 8.84% |
| Q1 2024 | -17.54% |
| Q4 2023 | 11.42% |
| Q3 2023 | 0.00% |
| Q2 2023 | 6.92% |
| Q1 2023 | -22.84% |
| Q4 2022 | 27.62% |
| Q3 2022 | -18.01% |
| Q2 2022 | 1.96% |
| Q1 2022 | -11.87% |
| Q4 2021 | 10.14% |
| Q3 2021 | -3.62% |
| Q2 2021 | 6.38% |
| Q1 2021 | -10.07% |
| Q4 2020 | 14.77% |
| Q3 2020 | 1.51% |
| Q2 2020 | -3.38% |
| Q1 2020 | -10.73% |
| Q4 2019 | 10.03% |
| Q3 2019 | -1.00% |
| Q2 2019 | 7.66% |
| Q1 2019 | -24.39% |
| Q4 2018 | 35.05% |
| Q3 2018 | -6.70% |
| Q2 2018 | 6.43% |
| Q1 2018 | -18.73% |
| Q4 2017 | 9.87% |
| Q3 2017 | -3.36% |
| Q2 2017 | 9.62% |
| Q1 2017 | -9.54% |
| Q4 2016 | 12.88% |
| Q3 2016 | -6.82% |
| Q2 2016 | 10.41% |
| Q1 2016 | -14.93% |